We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Avastin for Post-Photocoagulation Macular Edema

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00801866
Recruitment Status : Completed
First Posted : December 4, 2008
Last Update Posted : December 4, 2008
Information provided by:

Study Description
Brief Summary:
to evaluate the efficacy of a single intravitreal bevacizumab (IVB) injection, 0.1mL (2.5mg), against panretinal photocoagulation (PRP)-induced macular thickening and visual disturbance in patients with severe nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) and good vision

Condition or disease Intervention/treatment Phase
Macular Edema Drug: Bevacizumab Procedure: Panretinal Photocoagulation Phase 4

Study Design

Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: Prevention of Post-Photocoagulation Macular Edema by Intravitreal Bevacizumab.

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Edema
Drug Information available for: Bevacizumab
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Group 1
Panretinal Photocoagulation + Bevacizumab
Drug: Bevacizumab
Intravitreal administration
Experimental: Group 2
Panretinal Photocoagulation
Procedure: Panretinal Photocoagulation
Panretinal Photocoagulation

Outcome Measures

Primary Outcome Measures :
  1. Best Corrected Visual Acuity

Secondary Outcome Measures :
  1. Central Retinal Thickness.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   15 Years to 80 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with Proliferative retinopathy or severe non-proliferative retinopathy
  • BCVA of 20/63 or better (56 ETDRS letters
  • No history of Macular Edema
  • Central Retinal Thickness of 250mics or more

Exclusion Criteria:

  • Previous treatment.
  • Other ophthalmic diseases. history of Nephropathy, heart diseases and pregnancy
  • Media opacities
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00801866

Asociación para Evitar la Ceguera en México
Mexico, DF, Mexico, 04030
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Study Director: Eduarto Torres-Porras, MD Asociación para Evitar la Ceguera en México
Principal Investigator: Octavio Burgos, MD Asociación para Evitar la Ceguera en México
More Information

ClinicalTrials.gov Identifier: NCT00801866     History of Changes
Other Study ID Numbers: APEC-035
First Posted: December 4, 2008    Key Record Dates
Last Update Posted: December 4, 2008
Last Verified: December 2008

Keywords provided by Asociación para Evitar la Ceguera en México:
Panretinal Photocoagulation
Macular Edema
Intravitreal Bevacizumab

Additional relevant MeSH terms:
Macular Edema
Signs and Symptoms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents